- Fycompa(R) (perampanel) for the adjunctive treatment for partial onset
seizures, with or without secondarily generalised seizures, in patients with epilepsy
aged 12 years and older
- Zonegran(R) (zonisamide) as monotherapy in the treatment of partial seizures,
with or without secondary generalisation, in adults with newly diagnosed epilepsy and
as adjunctive therapy in the treatment of partial seizures, with or without secondary
generalisation, in adults, adolescents, and children aged 6 years and above (Zonegran
is under license from the originator Dainippon Sumitomo Pharma)
- Zebinix(R) (eslicarbazepine acetate) as adjunctive therapy in adults with
partial onset seizures, with or without secondary generalisation (Zebinix is under
license from BIAL)
- Inovelon(R) (rufinamide) for the adjunctive therapy in the treatment of
seizures associated with Lennox-Gastaut syndrome (LGS) in patients four years of age
and older (Rufinamide was originally developed by Novartis)
About Eisai
Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).
Eisai concentrates its R&D activities in three key areas:
- Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight
management
- Oncology including: anticancer therapies; tumour regression, tumour
suppression, antibodies, etc.
- Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
arthritis, psoriasis, inflammatory bowel disease
With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. From its EMEA Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business operations to include Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales and marketing operations in over 20 markets, including the United Kingdom, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Norway, Portugal, Russia, Slovakia, Spain, Switzerland, Sweden, the Netherlands and the Middle East.
For further information please visit our web site: http://www.eisai.co.uk
References
1. Data on file, Eisai Co. Ltd
2. Fycompa, Summary of Product Characteristics (updated November 2013 ):http://www.medicines.org.uk/emc/medicine... [http://www.medicines.org.uk/emc/medicine... ] [http://www.medicines.org.uk/emc/medicine... ]
3. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Currents 2011:11:56-63
4. Blumenfeld H et al. Cortical and subcortical networks in human secondarily generalized tonic-clonic seizures. Brain. 2009:132:999-1012
5. Epilepsy Action. Generalised seizures.https://www.epilepsy.org.uk/info/seizure... (accessed June 2014)
6. Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe.http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510... [http://www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf ] [http://www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf ] (accessed June 2014)
7. Pugliatti M et al. Estimating the cost of epilepsy in Europe: A review with economic modeling. Epilepsia 2007:48(12):2224-2233
Date of preparation: June 2014
Job code: Perampanel-UK2165
CONTACT: Media Enquiries Eisai Europe Ltd Cressida Robson/Ben Speller+44(0)7908-314-155/+44(0)845-676-1607 Cressida_Robson@eisai.netBen_Speller@eisai.net Tonic Life Communications Frances Murphy/NicolaLilley +44(0)207-798-9262 /+44(0)207-798-9905 frances.murphy@toniclc.comnicola.lilley@toniclc.com
